X

Trial Profile

Efficacy Study About Donor Derived CD19-target T Cell to Treat B-ALL Post Hematopoietic Stem Cell Transplantation

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IM19 chimeric antigen receptor T cell therapy Beijing Immunochina Medical Science and Technology (Primary) ; Cyclophosphamide; Fludarabine
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use
Sponsors Beijing Immunochina Medical Science and Technology

Most Recent Events

15 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
15 Dec 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Dec 2021.
08 Apr 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com